NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Not yet recruiting | N/A | 60 | Europe | 68Ga-PSMA-PET/CT scan, Online patient reported outcome measure (PROM) questionnaires, Blood sampling | The Netherlands Cancer Institute, Bayer | mCRPC, Male Urogenital Diseases | 07/29 | 07/29 | | |
